Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Recursion Pharmaceuticals Inc’s stock clocked out at $4.2, down -3.00% from its previous closing price of $4.33. In other words, the price has decreased by -$3.00 from its previous closing price. On the day, 17.02 million shares were traded. RXRX stock price reached its highest trading level at $4.36 during the session, while it also had its lowest trading level at $4.1435.
Ratios:
To gain a deeper understanding of RXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.60 and its Current Ratio is at 4.60. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.Needham initiated its Buy rating on March 16, 2023, with a $17 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when Gibson Christopher sold 40,000 shares for $4.63 per share. The transaction valued at 185,200 led to the insider holds 933,839 shares of the business.
Borgeson Blake sold 220,000 shares of RXRX for $961,400 on Dec 02 ’25. The Director now owns 6,869,863 shares after completing the transaction at $4.37 per share. On Dec 04 ’25, another insider, Gibson Christopher, who serves as the Officer of the company, bought 40,000 shares for $4.63 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2189303552 and an Enterprise Value of 1601416320. For the stock, the TTM Price-to-Sale (P/S) ratio is 50.03 while its Price-to-Book (P/B) ratio in mrq is 1.97. Its current Enterprise Value per Revenue stands at 36.655 whereas that against EBITDA is -2.511.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.94, which has changed by -0.39185393 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -17.18%, while the 200-Day Moving Average is calculated to be -19.46%.
Shares Statistics:
It appears that RXRX traded 42.95M shares on average per day over the past three months and 19065490 shares per day over the past ten days. A total of 485.21M shares are outstanding, with a floating share count of 431.60M. Insiders hold about 17.07% of the company’s shares, while institutions hold 48.82% stake in the company. Shares short for RXRX as of 1764288000 were 151875532 with a Short Ratio of 3.54, compared to 1761868800 on 128586047. Therefore, it implies a Short% of Shares Outstanding of 151875532 and a Short% of Float of 30.91.
Earnings Estimates
Investors are keenly observing as 5.0 analysts analyze and rate. The current performance of Recursion Pharmaceuticals Inc (RXRX) in the stock market.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.33 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.48 and -$1.73 for the fiscal current year, implying an average EPS of -$1.61. EPS for the following year is -$1.25, with 8.0 analysts recommending between -$1.07 and -$1.41.
Revenue Estimates
In. The current quarter, 6 analysts expect revenue to total $25.68M. It ranges from a high estimate of $46.4M to a low estimate of $17.1M. As of. The current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $4.55MFor the next quarter, 6 analysts are estimating revenue of $16.28M. There is a high estimate of $20.2M for the next quarter, whereas the lowest estimate is $10M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $85.5M, while the lowest revenue estimate was $48.35M, resulting in an average revenue estimate of $62.9M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $93.52M in the next fiscal year. The high estimate is $208.4M and the low estimate is $61.1M.
